EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Bactiquant AS (BACTIQ) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Bactiquant AS DKK 0.29, price DKK 2.07, upside -86.0%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Industrials · DK · ISIN DK0061417730

BA Thin data Sep 24, 2026

Bactiquant AS

BACTIQ · CO

Weakest SetupStrongly overvalued and low quality.

!Fair value kr 0.2890 · Strongly overvalued (−86%)
!Quality 37/100
!Weak Growth (revenue 5y +8.7 %/yr)
!Loss-making · -166.3% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers (1/10)
!Narrow moat 10/100
!Evidence only low, so the estimate is less certain
!Weak on future: 7 out of 100
Watch Bactiquant AS for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 14.02 kr 1.95 Fair Value kr 0.2890 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range kr 1.95 – kr 14.02 · fair‑value band kr 0.1870 – kr 0.3570 · the kr 2.07 price screens above the kr 0.2890 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Bactiquant AS in your weekly email

Every Wednesday you see whether Bactiquant AS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

BactiQuant A/S develops, produces, and provides technology for the mobile and online surveillance of bacterial contamination levels in water. The company offers Mobile Lab, a handheld tool for pollution tracking; BQ Online 2.0 PRO, an online solution to quantify the bacteria in water systems; and a range of analysis kits to monitor water quality.

Show more

BactiQuant A/S develops, produces, and provides technology for the mobile and online surveillance of bacterial contamination levels in water. The company offers Mobile Lab, a handheld tool for pollution tracking; BQ Online 2.0 PRO, an online solution to quantify the bacteria in water systems; and a range of analysis kits to monitor water quality. It serves various industries in the areas of aquaculture, data centers, oil and gas, water utility, industry, and pharma. The company was founded in 1999 and is based in Horsholm, Denmark.

Stock analysis

Bactiquant AS (BACTIQ) currently trades at kr 2.07, while our model-based Fair Value estimate is kr 0.2890, implying the stock looks roughly 616.3% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: kr 0.1870 (bear) to kr 0.3570 (bull), the price of kr 2.07 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Industrials sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Bactiquant AS reported revenue of 8.3M DKK in FY2025 versus 8.4M DKK in FY2021, a compound −0.1%/yr. Reported net income was −13.8M DKK in FY2025.

Key figures

Market cap 87.4M DKK (≈ $13.3M) · P/S ratio 10.5 · EPS (TTM) kr −0.4600 · Net margin −166% · Return on equity −154% · Return on assets (EBIT) −56.8% · Operating margin −146% · Revenue (TTM) 8.3M DKK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (low confidence).

What moves the price

The share trades about 48% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Industrials peers we cover trades at −28% fair-value upside, at −86%, BACTIQ screens richer than that median.

Fair Value models

Bear kr 0.1870 Fair Value kr 0.2890 Bull kr 0.3570
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) kr 0.2300 kr 0.3100 kr 0.4600 54
All 1 models by family
Asset-Based
NCAV (Graham) kr 0.2300 kr 0.3100 kr 0.4600 54

Open the full fair value analysis →

Notify me when BACTIQ reaches fair value

Put BACTIQ on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 37/100

Of which business quality 39 · Market factors (momentum, volatility) 24

Profitability 3
Margins and returns on capital today
Quality Growth 74
Are margins and returns improving?
Cashflow 6
Earnings quality: real cash, not paper profit
Fin. Strength 92
Balance sheet, leverage, solvency risk
Investment 78
Disciplined investing over empire-building
Low Volatility 49
Calm price path (market factor)
Momentum 19
Price trend over the last 3–12 months (market factor)
52W Momentum 6
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 32/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+15.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.7%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−23.6% (2020) → −150.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

BACTIQ screens 616% overvalued. Compare with Veralto Corporation →

Compare Bactiquant AS with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pollution & Treatment Controls · 94 stocks

Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 39 · Bottom 25%
Fair Value upside −86% · Bottom 25%
Profitability
Return on assets −37% · Bottom 25%
Net margin (TTM) −166% · Bottom 25%
Operating margin (TTM) −146% · Bottom 25%
Growth and dividend
Revenue growth 1% · Below median
Balance sheet
Debt / equity 0.39× · Highest 25%

Valuation Multiplesvs Pollution & Treatment Controls median · lower = cheaper

P/B 0.77× · Cheaper than median
P/S (TTM) 1.60× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 3
FUTURE (revenue growth)7 · sector 11
PAST (return on equity)0 · sector 18
HEALTH (low debt)80 · sector 94
DIVIDEND (yield)0 · sector 37

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pollution & Treatment Controls stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Veralto Corporation VLTO $95.79 $69.11 −28%
Zurn Elkay Water Solutions Corporation ZWS $46.91 $49.84 +6%
Canmax Technologies Co 300390 ¥54.23 ¥10.07 −81%
CECO Environmental Corp CECO $73.71 $15.27 −79%
Fujian Longking Co 600388 ¥17.22 ¥15.59 −9%
Munters Group MTRS kr 136.05 kr 48.58 −64%
China Conch Venture Holdings 0586 HK$7.59 HK$14.40 +90%
Mega Union Technology Inc 6944 760.00 TWD 836.00 TWD +10%
Hebei Sailhero Environmental Protection High-tech Co 300137 ¥11.49 ¥2.24 −81%
MayAir Technology (China) Co 688376 ¥65.14 ¥18.80 −71%

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Bactiquant AS · Fair Value
kr 0.2890 −616%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Bactiquant AS Fair Value". https://www.fairvalue-calculator.com/stock/BACTIQ

Frequently asked questions

Is Bactiquant AS (BACTIQ) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of kr 0.2890 versus a price of kr 2.07, about −86% upside (overvalued).
What is the fair value of BACTIQ?
Our model-based fair value for Bactiquant AS is kr 0.2890 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 2.07.
What is the quality score of BACTIQ?
Bactiquant AS has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bactiquant AS (BACTIQ)?
Our model-based price target is the fair value of kr 0.2890 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario kr 0.1870, optimistic scenario kr 0.3570. It is a calculation from audited fundamentals, not an analyst target.
What is the Bactiquant AS stock forecast for 2026?
Our models put fair value at kr 0.2890, about −86% upside versus a price of kr 2.07 (overvalued). Cautious scenario kr 0.1870, optimistic scenario kr 0.3570. The calculation is refreshed regularly with new filings.
What is the revenue of Bactiquant AS (BACTIQ)?
Bactiquant AS reported trailing-twelve-month revenue of about 8.3M DKK (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Bactiquant AS (BACTIQ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bactiquant AS it is kr 0.2890 per share (as of Sep 24, 2026), against a price of kr 2.07. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Bactiquant AS stock overvalued or undervalued in 2026?
As of Sep 24, 2026, BACTIQ trades above its calculated fair value: price kr 2.07, fair value kr 0.2890, a gap of about −86% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BACTIQ?
No. The price is what the market pays today (kr 2.07); the fair value is what the company's own numbers justify (kr 0.2890). For Bactiquant AS the two are kr 1.78 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bactiquant AS worth?
The market values Bactiquant AS at about 87.4M DKK (market capitalisation, as of Sep 24, 2026). Per share that is kr 2.07; our models calculate a fair value of kr 0.2890 per share.
What do the bullish and bearish scenarios say about BACTIQ?
Our models span a range for Bactiquant AS: cautious scenario kr 0.1870, base kr 0.2890, optimistic kr 0.3570 per share (as of Sep 24, 2026, price kr 2.07). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Bactiquant AS (BACTIQ)?
Balance-sheet figures for Bactiquant AS (as of Sep 24, 2026): return on equity −154.1%, debt of 0.39 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is BACTIQ from its 52-week high?
Bactiquant AS trades at kr 2.07, about 48% below its 52-week high of kr 3.95 and at the low of kr 2.07 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.2890 is for.
Which stocks are comparable to Bactiquant AS?
From the same area (Industrials) we also value Veralto Corporation, Zurn Elkay Water Solutions Corporation, Canmax Technologies Co, CECO Environmental Corp, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bactiquant AS stock attractive at the current price?
The data as of Sep 24, 2026: price kr 2.07, calculated fair value kr 0.2890 (−86%), Quality Score 37/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BACTIQ calculated?
We run Bactiquant AS through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.2890, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Bactiquant AS itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bactiquant AS (BACTIQ)?
The closing price on Sep 24, 2026 was kr 2.07. Our model-based fair value is kr 0.2890, about −86% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bactiquant AS right now?
The price sits above even our optimistic bull case (kr 0.3570). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 0.1870 to kr 0.3570) leaves room in how you read the outcome.

Key figures of Bactiquant AS

How large is the market capitalisation of Bactiquant AS (BACTIQ)?
The market capitalisation of Bactiquant AS is 87.4M DKK (≈ $13.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bactiquant AS (BACTIQ)?
The price-to-sales ratio of Bactiquant AS is 10.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bactiquant AS (BACTIQ)?
Earnings per share at Bactiquant AS are kr −0.4600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Bactiquant AS (BACTIQ)?
The net margin of Bactiquant AS is −166% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bactiquant AS (BACTIQ)?
The return on equity (ROE) of Bactiquant AS is −154% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bactiquant AS (BACTIQ)?
On an EBIT basis the return on assets of Bactiquant AS is −56.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bactiquant AS (BACTIQ)?
The operating margin of Bactiquant AS is −146% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bactiquant AS (BACTIQ)?
Revenue at Bactiquant AS is growing +1.4% versus a year earlier (3y avg −12.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Bactiquant AS (BACTIQ) generate?
The free cash flow of Bactiquant AS is −10.5M DKK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Bactiquant AS (BACTIQ) hold?
Bactiquant AS holds more cash than debt, 9.6M DKK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Bactiquant AS in the live analysis

One click puts Bactiquant AS on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.